Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval

Simply Wall St.02-26

Harmony Biosciences Holdings recently reported Q4 2025 results showing net income of US$22.49 million and diluted EPS of US$0.38, alongside full-year 2025 net income of US$158.69 million and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614118570?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-26 16:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614118570","market":"nz","top_or_hot":-1,"title":"Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval","media":"Simply Wall St.","content":"<div>\n<p>Harmony Biosciences Holdings recently reported Q4 2025 results showing net income of US$22.49 million and diluted EPS of US$0.38, alongside full-year 2025 net income of US$158.69 million and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-hrmy-is-down-201-after-reaffirming-wakix\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-26 16:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-hrmy-is-down-201-after-reaffirming-wakix><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Harmony Biosciences Holdings recently reported Q4 2025 results showing net income of US$22.49 million and diluted EPS of US$0.38, alongside full-year 2025 net income of US$158.69 million and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-hrmy-is-down-201-after-reaffirming-wakix\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-hrmy-is-down-201-after-reaffirming-wakix","article_id":"2614118570","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-hrmy-is-down-201-after-reaffirming-wakix","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614118570","pubTimestamp":1772094724,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Harmony Biosciences Holdings recently reported Q4 2025 results showing net income of US$22.49 million and diluted EPS of US$0.38, alongside full-year 2025 net income of US$158.69 million and reiterated 2026 WAKIX net revenue guidance of US$1.00 billion to US$1.04 billion.\nAt the same time, FDA approval extending WAKIX to treat cataplexy in pediatric narcolepsy patients and progress securing its intellectual property framework could be important for Harmony’s long-term WAKIX franchise and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc.","BK4007":"制药"},"translate_title":"Harmony Biosciences(HRMY)在重申WAKIX前景并获得儿科批准后股价下跌20.1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":1.5},"content_text":"Harmony Biosciences Holdings recently reported Q4 2025 results showing net income of US$22.49 million and diluted EPS of US$0.38, alongside full-year 2025 net income of US$158.69 million and reiterated 2026 WAKIX net revenue guidance of US$1.00 billion to US$1.04 billion. At the same time, FDA approval extending WAKIX to treat cataplexy in pediatric narcolepsy patients and progress securing its intellectual property framework could be important for Harmony’s long-term WAKIX franchise and broader pipeline ambitions. We’ll now examine how the pediatric cataplexy approval and reaffirmed blockbuster WAKIX guidance may influence Harmony Biosciences’ investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementHarmony Biosciences Holdings Investment Narrative RecapTo own Harmony Biosciences, you need to believe WAKIX can sustain its role as a high-value narcolepsy therapy while the company broadens its neurology franchise. The pediatric cataplexy approval and reaffirmed 2026 WAKIX guidance support the near term growth story, while the key risk remains concentration in a single asset and uncertainty around future market exclusivity and competition, including ongoing intellectual property challenges. The most relevant update here is Harmony’s reaffirmed 2026 WAKIX net revenue guidance of US$1.00 billion to US$1.04 billion. That guidance now sits alongside expanded pediatric labeling and progress on settlements with most generic challengers, framing WAKIX not just as the core earnings driver today but also as the central lever behind upcoming catalysts such as new formulations and potential label expansions. Yet beneath the upbeat guidance, investors should be aware of how unresolved IP disputes and eventual generic entry could... Read the full narrative on Harmony Biosciences Holdings (it's free!)Harmony Biosciences Holdings' narrative projects $1.2 billion revenue and $333.5 million earnings by 2028. This requires 17.0% yearly revenue growth and about a $152.6 million earnings increase from $180.9 million today.Uncover how Harmony Biosciences Holdings' forecasts yield a $47.30 fair value, a 68% upside to its current price.Exploring Other PerspectivesHRMY 1-Year Stock Price Chart Some of the lowest ranked analysts were already cautious, assuming revenue of about US$1.1 billion and earnings near US$263 million by 2028, and their focus on concentration and reimbursement risk offers a useful counterpoint to the recent WAKIX guidance and pediatric approval, reminding you that expectations can differ widely and may shift again once this new information is fully reflected.Explore 5 other fair value estimates on Harmony Biosciences Holdings - why the stock might be worth over 6x more than the current price!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Harmony Biosciences Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.Want Some Alternatives?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Uncover the next big thing with 30 elite penny stocks that balance risk and reward.Outshine the giants: these 23 early-stage AI stocks could fund your retirement.We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Harmony Biosciences Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614118570","isCrawlerRequest":true}